Phase 2
It was yet another busy week for clinical trial announcements. Take a look.
The news of a unanimous decision by the adcom came just two days after the agency issued a 45-page document that contained vague comments on the drug.
BrainStorm announced positive data from a Phase II safety and efficacy study of NurOwn in progressive MS on Thursday morning.
Modern radiation therapy is tightly targeted to dramatically reduce toxicity and side effects and often can be administered on an outpatient basis.
Less private investment and innovation in the development of new antibiotics are impeding efforts to combat drug-resistant infections.
Variety, passion and the ability to make tangible improvements in people’s lives have propelled John Fowler, co-founder and CEO of Kezar Life Sciences, throughout his career.
This year – 2021 – will be a transformational year, Rosen predicted, citing three important milestones.
Mirati and Sanofi will assess the combination of adagrasib and SAR442720 in a Phase I/II study in patients with previously treated non-small-cell lung cancer who express KRASG12C mutations.
Based on results from the Phase II and Phase III TAK-620-303 (SOLSTICE) trials, members of the AMDAC unanimously voted in favor of using maribavir.
PRESS RELEASES